USA-based Harvard University's Office of Technology Development plans to integrate its discoveries in the nanopore area with technology in development by the UK's Oxford Nanopore Technologies.
Under the terms of this agreement, Oxford Nanopore has exclusive rights to develop and commercialize a number of nanopore technological breakthroughs developed in the laboratories of three investigators at Harvard and their collaborators at the University of California Santa Cruz and the National Institute of Standards and Technology, an agency of the US Department of Commerce.
According to the firms, these academics have pioneered the research of DNA translocation through nanopores and the potential for DNA sequencing using this method.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze